P3‐022: INDIVIDUALIZED SYMPTOM TRACKING WITH SYMPTOMGUIDETM ALLOWS FOR CLINICALLY MEANINGFUL INTERPRETATION OF MMSE SCORE CHANGES IN A DEMENTIA DRUG TRIAL. (1st July 2019)